Emma Walmsley
Walmsley has held the top job at GSK, the $38.9 billion British pharma firm, for 17 months, and she has been quick in bringing change to the 300-year old company. In March, she purchased Novartis’s 36% stake in GSK Consumer Health, the joint venture the two firms formed in 2014 and which, as one of the world’s largest OTC businesses, did $9.4 billion in sales last year. In July, she did a $300 million deal with 23andMe, the data-rich direct-to-consumer genetic testing company, to collaborate on drug development. She’s hired a high profile roster of talent from across the industry and beyond—poaching executives from AstraZeneca, Novartis, Pfizer, Walmart and HSBC among others—and putting them to work on her No. 1 agenda item: reinvigorating drug development at the company.
Read: CEO Emma Walmsley’s Bold Prescription for Reviving GlaxoSmithKline
Personal Information |
|
|---|---|
| Country | U.K. |
| Previous Rank | 2 |
| Newcomer? | - |
Company Financials |
Millions ($) |
|---|---|
| 2017 Profits | 1,972.6 |
| 2017 Revenues | 38,867.8 |
| Market Value as of 08/30/18 ($M) | 102,588.5 |
